Glox Therapeutics
Drug Discovery
- [email protected]
- Website
- https://gloxtherapeutics.com/
- Membership category
- Emerging Y1
Arbuthnott Building - Hamnett Wing, 161 Cathedral Street, Glasgow, G4 0RE, United Kingdom
About Glox Therapeutics
Glox Therapeutics is developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality. These novel precision antibiotics have potent narrow-spectrum activity to target Gram-negative AMR pathogens without collateral damage to the wider human microbiome.
Founded in 2023, the company is built out of over 20 years of research at the Universities of Glasgow and Oxford from globally recognised expertise in elucidating bacteriocin structure and function to treat bacterial infections. It is uniquely positioned to address the AMR public health crisis which is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars by 2050.
The company is supported by a highly expert network of scientific advisers and has received investment and support from high-profile investors the Boehringer Ingelheim Venture Fund and Scottish Enterprise.
